Side Effects of Genetically Engineered Biological Agents in Treatment of Immune and Inflammatory Diseases
DOI:
https://doi.org/10.61788/njn.v1i19.02Keywords:
genetically engineered drugs (GED), biological agents, autoimmune diseases, monoclonal antibodiesAbstract
In the present review article, we discuss side effects associated with the use of a new group of drugs, called recombinant or genetically engineered drugs (GED). Considered adverse reactions arising from the use of individual GIBP.
References
Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis // Lancet. 2016; 388: P. 2023-38. doi:10.1016/S0140-6736(16)30173-8.
Насонов Е.Л., Каратеев Д.Е. Применение генно-инженерных биологических препаратов для лечения ревматоидного артрита: общая характеристика (лекция) // Научно-практическая ревматология. 2013;51(2):163-169. https://doi.org/10.14412/1995-4484-2013-645.
Siebert S., Tsoukas A., Robertson J., McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases // Pharmacol Rev., 2015;67: P. 280-309. doi: 10.1124/pr.114.009639.
Zhang Q., Vignali D.A. Co-stimulatory and co-inhibitory Pathways in Autoimmunity // Immunity. 2016 May 17;44(5): P. 1034-51. doi: 10.1016/j.immuni.2016.04.017.
Huscher D., Mittendorf T., von Hinuber U., et al. Evolution of coststructures in rheumatoid arthritis over the past decade // Ann Rheum Dis., 2015; 74: P. 738-45. doi: 10.1136/annrheumdis-2013-204311
Putrik P., Ramiro S., Kvien T.K., et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries // Ann Rheum Dis., 2014;73: P. 198-206. doi: 10.1136/annrheumdis-2012-202603
Putrik P., Ramiro S., Kvien T.K., et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth // Ann Rheum Dis. 2014;73: P. 2010-21. doi: 10.1136/annrheumdis-2013-203819
Dö rner T., Strand V., Castaneda-Hernandez G., et al. The role of biosimilars in the treatment of rheumatic diseases // Ann Rheum Dis. 2013;72: P. 322-8. doi: 10.1136/annrheumdis-2012-202715
Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology – ≪O Brave New World≫. Nat Rev Rheum.2012;8: P. 430-6. doi:10.1038/nrrheum.2012.84
Goel N., Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford). 2017; 56(2); P. 187-197.
Dö rner T., Strand V., Cornes P., et al. The changing landscape of biosimilars in rheumatology // Ann Rheum Dis. 2016;75: P. 974-82. doi: 10.1136/annrheumdis-2016 20
Haustein R., Millas C., Hö er A., Hä ussler B. Saving money in the European healthcare systems with biosimilars // Generics Biosimilars Initiat J. 2012;1: P. 120-6. doi: 10.5639/gabij.2012.0103-4.036
Dolinar R.O., Reilly M.S. Biosimilars naming, label transparency and authority of choice – survey findings among European physicians // Ga Bi J. 2014;3: P.58-62. doi: 10.5639/gabij.2014.0302.018
Guideline on similar biological medical products. European Medical Agency. VHMP/437/04.London, 30 October 2005.Available from: http:/www.emea.eu.int
WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs), annex 2. World Health Organ Tech Rep Ser.2013; 977: P. 53-89.
U.S. Food and Drug Administration. Biosimilars. Available from: https://bit.ly/3uXLIbx. Accessed 13 January 2016.
European Medicines Agency. Biosimilar Medicines. Available from: https://bit.ly/46VYaFP. Accessed 13 January 2016.
Федеральный закон от 22 декабря 2014 г. № 429-ФЗ ≪О внесении изменений в Федеральный закон "Об обращении лекарственных средств"≫. Принят Государственной Думой 9 декабря 2014 г. Одобрен Советом Федерации 17 декабря 2014 г.
U.S. Food and Drug Administration. Guidance for industry. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. 2015. Available from: https://bit.ly/3GKJ7V0. Accessed 14 January 2016.
European Medicines Agency. Guideline on similar biological medicinal products. 2014. Available from: https://bit.ly/4aoGGVJ. Accessed 2 February 2015.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. Available from: https://bit.ly/47WZ1aG. Accessed 7 January 2016.
U.S. Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. Available from: https://bit.ly/47WZaLg. Accessed 2 February 2015.
Schneider C.K. Biosimilars in rheumatology: the wind of change // Ann Rheum Dis. 2013; 72: P. 315-8. doi: 10.1136/annrheumdis-2012-202941
U.S. Food and Drug Administration. Guidance for industry. Q5e comparability of biotechnological/biological products subject to changes in their manufacturing process. 2005. Available from: https://bit.ly/47WZaLg. Accessed 20 January 2016.
Dorner T., Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt // Nat Rev Rheumatol. 2015; 11: P. 713-24. doi:10.1038/nrrheum.2015.110
U.S. Food and Drug Administration. Guidance for industry. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. 2015. Available from: https://bit.ly/41msDM4. Accessed 13 January 2016.
Braun J., Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health // Biologicals. 2016; 44: P. 257-66. doi: 10.1016/j.biologicals.2016.03.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
